心脏纤维化:从机制和模型到药物
Wenqiang Liu1, Xuekun Wu1, Wenshu Zeng1
1Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Trends in pharmacological sciences
|August 28, 2025
概括
心脏纤维化是心脏病的一个关键特征, 使用先进模型的新研究揭示了精确抗纤维治疗的新驱动因素和治疗策略.
科学领域:
- 心脏病学
- 生物医学工程
- 干细胞生物学
背景情况:
- 心脏纤维化是各种心血管和全身疾病的重要病理特征.
- 目前心脏纤维化治疗策略有限,没有FDA批准的直接针对纤维化改造的治疗方法.
- 疾病建模和转化方面的挑战阻碍了有效的抗纤维治疗的发展.
研究的目的:
- 审查导致心脏纤维化的新兴分子机制.
- 综合最近研究心脏纤维化的实验模型的进展.
- 巩固抗纤维素药物的临床前和临床研究结果.
主要方法:
- 对心脏纤维化机制和治疗发展的最新文献进行分析.
- 专注于人类诱导多能干细胞 (iPSC) 衍生模型,人工心脏组织和体内系统.
- 强调分子驱动因素和治疗点的跨语境对齐.
主要成果:
- 鉴定新的纤维化驱动因素,包括免疫性肌瘤交叉声响,代谢重编程和机械传导.
- 实验模型的进步为研究纤维化过程提供了更好的准确性.
- 新兴抗纤维剂在临床前和临床研究中显示出前景.
结论:
- 对纤维化驱动因素的新见解正在重塑心脏纤维化治疗的发展.
- 先进的模型对于理解和针对心脏纤维化至关重要.
- 跨语境对齐是开发精确抗纤维治疗的关键.
相关概念视频
Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Cardiomyopathy IV: Restrictive Cardiomyopathy
27
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
27


